Blog
RSS FeedPosted by Michael Wonder on 28 May 2025
Fresenius Kabi to announce the commercial launch of Otulfi, an approved ustekinumab biosimilar in Canada
27 May 2025 - Fresenius Kabi's ustekinumab biosimilar Otulfi is now commercially available for both subcutaneous and intravenous formulations. ...
Posted by Michael Wonder on 14 May 2025
Lilly Canada announces availability of Mounjaro KwikPen (tirzepatide) in all doses, advancing care for adults living with type 2 diabetes
13 May 2025 - The multi-dose, single-patient-use, pre-filled pen allows for personalised treatment plans that can cater to individual patient ...
Posted by Michael Wonder on 18 Mar 2025
Pfizer's Ixifi will be available in Canada as of 1 April 2025
17 March 2025 - Ixifi is available in more than 20 countries and was approved by Health Canada in December 2021. ...
Posted by Michael Wonder on 12 Mar 2025
Celltrion's infliximab, the first monoclonal antibody biosimilar, is now Remdantry in Canada
11 March 2025 - CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has ...
Posted by Michael Wonder on 12 Mar 2025
ACCRUFeR (ferric maltol) is now available in Canada as a prescription oral treatment for iron deficiency anaemia
11 March 2025 - ACCRUFeR is the only oral iron therapy approved as a prescription drug in Canada. ...
Posted by Michael Wonder on 05 Mar 2025
Skyrizi (risankizumab) now available for moderately to severely active ulcerative colitis, expanding AbbVie's portfolio across inflammatory bowel disease
4 March 2025 - Skyrizi is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and ...
Posted by Michael Wonder on 18 Oct 2024
Fresenius Kabi launches Tyenne, the first and only approved tocilizumab biosimilar in Canada
17 October 2024 - Tyenne is the first and only tocilizumab biosimilar to be launched in Canada. ...
Posted by Michael Wonder on 13 Aug 2024
Introducing Jubbonti and Wyost, the first denosumab biosimilars on the Canadian market
12 August 2024 - Jubbonti and Wyost are first denosumab biosimilars available in Canada, reflecting the Sandoz Purpose of pioneering access ...
Posted by Michael Wonder on 02 Aug 2024
Nordimet (methotrexate) self-injection pen now available in Canada for treatment of rheumatoid arthritis and psoriasis/psoriatic arthritis
1 August 2024 - Linepharma is pleased to announce that Nordimet (methotrexate), the first methotrexate single-use pre-filled pen for self-injection, ...
Posted by Michael Wonder on 25 Jul 2024
Kye Pharmaceuticals secures exclusive license, supply and commercialisation agreement with Catalyst Pharmaceuticals for Agamree, a novel treatment for Duchenne muscular dystrophy, in Canada
24 July 2024 - Kye Pharmaceuticals today announced that it has entered into a license, supply and commercialisation agreement with Catalyst ...
Posted by Michael Wonder on 03 Jul 2024
Kye Pharmaceuticals announces the availability of Quillivant ER chewable tablets for the treatment of children with ADHD
2 July 2024 - Quillivant ER chewable tablets are the first and only extended release chewable methylphenidate tablets approved in Canada. ...
Posted by Michael Wonder on 18 Jun 2024
Awiqli - world's first once-weekly basal insulin - now available in Canada
17 June 2024 - Novo Nordisk is pleased to announce Canada will be the first country worldwide to launch Awiqli (insulin ...
Posted by Michael Wonder on 13 Jun 2024
Adtralza (tralokinumab) pre-filled pen now available in Canada
12 June 2024 - The single-use 2 mL pre-filled pen is an additional injection choice for administering Adtralza for the ...
Posted by Michael Wonder on 23 May 2024
Pfizer announces availability of Abrysvo in Canada for immunisation of pregnant individuals and adults 60+
22 May 2024 - Availability of Arbysvo is a major step in protecting infants and adults 60 years of age ...
Posted by Michael Wonder on 12 Apr 2024
Formycon announces commercial launch of FYB201 (ranibizumab) in Canada (Ranopto) and Switzerland (Ranivisio)
11 April 2024 - Commercialization partner Teva markets FYB201 in Canada under the trademark Ranopto and in Switzerland under the trademark ...